

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM628519

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Myriad Genetics, Inc.		02/09/2021	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Myriad RBM, Inc.		
Street Address:	3300 Duval Road, Suite 110		
City:	Austin		
State/Country:	TEXAS		
Postal Code:	78759		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	4552583	ANGIOGENESISMAP	
Registration Number:	4657438	APOPTOSISMAP	
Registration Number:	4527033	IMMUNOMAP	
Registration Number:	4169261	MYRIAD RBM	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	678-632-6933		
Email:	anne.keenan-yates@fisherbroyles.com		
Correspondent Name:	Anne E. Keenan-Yates		
Address Line 1:	1029 Peachtree Parkway North, Suite 195		
Address Line 2:	FisherBroyles LLP		
Address Line 4:	Peachtree City, GEORGIA 30269		
NAME OF SUBMITTER:	Anne E. Keenan-Yates		
SIGNATURE:	/Anne E. Keenan-Yates/		
DATE SIGNED:	02/26/2021		
Total Attachments: 6			
source=Myriad Trademark Assignment- executed#page1.tif			
source=Myriad Trademark Assignment- executed#page2.tif			

OP \$115.00 4552583

source=Myriad Trademark Assignment- executed#page3.tif
source=Myriad Trademark Assignment- executed#page4.tif
source=Myriad Trademark Assignment- executed#page5.tif
source=Myriad Trademark Assignment- executed#page6.tif

TRADEMARK ASSIGNMENT

THIS TRADEMARK ASSIGNMENT (the "Assignment") is made and entered into as of the 9th day of February 2021, by and between Myriad Genetics, Inc., a Delaware corporation, whose address is 320 Wakara Way, Salt Lake City, Utah USA 84108 ("Assignor") and Myriad RBM, Inc., a Delaware corporation, whose address is 3300 Duval Road, Suite 110, Austin, Texas USA 78759 ("Assignee") (collectively, the "Parties").

WITNESSETH

WHEREAS, Assignor has adopted and used and is the owner of the marks ANGIOGENESISMAP, APOPTOSISMAP, CUSTOMMAP, IMMUNOMAP, and MYRIAD RBM, including but not limited to the registrations set forth on Schedule A and incorporated herein by reference (collectively, the "Marks");

WHEREAS, Assignor is the owner of all right, title, and interest in and to the Marks set forth on Schedule A;

WHEREAS, the Parties desire to enter into this Assignment to affect the transfer of all right, title, and interest in and to the Marks to Assignee on a worldwide basis, including but not limited to the registrations set forth on Schedule A; and

NOW, THEREFORE, for and in consideration of the premises and the mutual promises hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. Transfer and Assignment. Assignor hereby transfers and assigns to Assignee all right, title, and interest in and to the Marks on a worldwide basis, including but not limited to the registrations set forth on Schedule A, together with the goodwill associated therewith, along with the right to recover for damages and profits and other remedies for past infringements of the Marks.

2. Further Documentation and Actions. Assignor hereby agrees to execute and deliver to Assignee any further documents and instruments, and to do any and all further reasonable acts that are reasonably necessary to vest in Assignee all right, title, and interest in and to the Marks, and to enable such right, title, and interest to be recorded in the United States Patent and Trademark Office, European Union Intellectual Property Office, Canadian Intellectual Property Office, Japan Patent Office, China National Intellectual Property Administration, and any other appropriate governmental authority or agency of the United States and internationally.


3. Severability. If any term, clause, language, or provision of this Assignment is held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall not affect the validity or operation of any other term, language, clause, or provision, and such invalid term, clause, or provision shall be deemed to be severed.

4. Construction; Governing Law; Entire Agreement. This Agreement: (a) is governed by Delaware law with respect to contract formation, construction, and interpretation; and U.S. federal trademark law as to trademark issues; (b) may not be amended except by a writing executed by the Parties; (c) represents the entire agreement between the Parties regarding the Marks; (d) may be executed in multiple counterparts by the Parties which, taken together, shall constitute one binding

agreement; and (e) shall be binding upon and shall inure to the benefit of the Parties and each of their respective successors, assigns, heirs, and beneficiaries.

“ASSIGNOR”

MYRIAD GENETICS INC.


By: 
0312C0C52FAB4C2...

Name: Benjamin G. Jackson

Title: Exec VP General Counsel

“ASSIGNEE”


MYRIAD RBM, INC.



By: 
967EFD567CB44B0...



Name: Ralph McDade

Title: President, Myriad RBM

SCHEDULE A

Country/ Territory	Mark	Filing/ Registration Date	Serial/ Registration Number	Intl. Class	Goods/Services
European Union	ANGIOGENESISMAP	06/03/2013	1166423	42	Biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs and the environment
U.S.A.	ANGIOGENESISMAP	06/07/2014	4,552,583	42	Biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs and the environment
U.S.A.	APOPTOSISMAP	12/16/2014	4,657,438	42	Biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs and the environment
European Union	CUSTOMMAP	12/05/2013	1189105	42	Customizable biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs and the environment
U.S.A.	IMMUNOMAP	05/06/2014	4,527,033	42	Biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs and the environment
China	MYRIAD RBM & Design 	01/18/2012	G1111257	42	Clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and

					trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others
European Union	MYRIAD RBM & Design MYRIAD  RBM	01/18/2012	1,111,257	42	Clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others
Japan	MYRIAD RBM & Design MYRIAD  RBM	01/18/2012	1,111,257	42	Clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and trials for pharmaceutical

					development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others
Canada	MYRIAD RBM & Design MYRIAD  RBM	02/21/2013	TMA844257	42	Clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others
U.S.A.	MYRIAD RBM & Design MYRIAD  RBM	07/03/2012	4,169,261	42	Clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and trials for pharmaceutical development purposes; and

					research and development of new diagnostic products and pharmaceutical drug services for others
--	--	--	--	--	--